Trials Sponsors Conditions Drugs Pricing

Conditions

Knee Osteoarthritis Obesity

Keywords

EcnoglutideKOAObesity

Outcome Measures

Primary Outcomes (2)

Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Baseline, week 68
Percentage Change in Body Weight
Baseline, week 68

Secondary Outcomes (32)

Percentage of Participants with ≥5% of Body Weight Loss
Baseline, week 68
Percentage of Participants with ≥10% of Body Weight Loss
Baseline, week 68
Percentage of Participants with ≥50% of Reduction in WOMAC Pain Subscale Score
Baseline, week 68
Change in WOMAC Physical Function Subscale Score
Baseline, week 68
Change in Short Form 36 (SF36) V2 Physical Function Subscale Score
Baseline, week 68
+27 more secondary outcomes

Study Arms (2)

Ecnoglutide Injection

EXPERIMENTAL

Once weekly

Drug: Ecnoglutide Injection

Placebo

PLACEBO COMPARATOR

Once weekly

Drug: placebo with matching volume

Interventions

Ecnoglutide InjectionDrug

subcutaneous injection

Ecnoglutide Injection

placebo with matching volumeDrug

subcutaneous injection

Placebo

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Body mass index (BMI) ≥ 28.0 kg/m\^2;
The target knee must meet the diagnostic criteria of American College of Rheumatology (ACR) for knee osteoarthritis (clinical and radiological), with moderate radiographic changes (Kellgren-Lawrence grade 2 or 3). The target knee is defined as the knee with the most symptomatic knee at screening period; if pain in both knees are equal, the target knee will be the most dominant leg (preferred leg);

Sponsors & Collaborators

Hangzhou Sciwind Biosciences Co., Ltd.
Industrylead

Study Sites (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

RECRUITING

Weihua XU, DrCONTACTxuweihua@hust.edu.cn

MeSH Terms

Conditions

Osteoarthritis, KneeObesity

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

Weihua XU
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PRINCIPAL INVESTIGATOR

Central Study Contacts

Yao Li

CONTACT

010-67889255 ra@sciwindbio.com

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, INVESTIGATOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 21, 2026

First Posted

July 29, 2026

Study Start

August 3, 2026

Actual (reported)

Primary Completion

May 31, 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

You may not qualify if:

The target knee has undergone joint replacement surgery;
The target knee has undergone arthroscopy within 12 months prior to screening;
At the time of screening, the target knee joint has any clinical features and symptoms of other active infections or crystal-induced arthropathies, as well as any other active joint diseases that may interfere with assessment;
The target knee has received intra-articular injections of hyaluronic acid, any other investigational drugs, or biologics within 3 months prior to screening; or has undergone any procedures that result in persistent sensory loss in the target knee (e.g., ablation) within 6 months prior to screening;
Has received any intramuscular or oral corticosteroids (investigational or marketed) within 30 days prior to screening, or has received any intra-articular corticosteroid injections (investigational or marketed) in any joint within 90 days prior to screening;
History of joint instability in either knee within 12 months prior to screening, such as anterior cruciate ligament rupture or recent trauma;
History of any other potentially causative and/or confounding diseases, including Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease-associated arthritis, sarcoidosis, amyloidosis, or fibromyalgia;
Presence of symptomatic hip osteoarthritis at the time of screening, with the exception of those who have undergone hip replacement surgery;
Conditions that may interfere with the assessment of target knee pain during screening include, but are not limited to:
Pain in any part of the lower limb or back equal to or more severe than the pain in the target knee;
Pain radiating to the knee from other areas, such as hip pain affecting the knee or radicular pain;
Chronic widespread pain (including neuropathic pain);
Change of body weight \>5% within 3 months prior to screening (selfreported);
Diagnosis of diabetes (excluding gestational diabetes), or with a history of diabetic ketoacidosis or hyperosmolar state/coma

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (32)

Study Arms (2)

Ecnoglutide Injection

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (32)

Study Arms (2)

Ecnoglutide Injection

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations